Ivermectin in Treatment of COVID-19

Zagazig University100 enrolled

Overview

confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

COVID

Interventions

IvermectinDRUG

3 successive days ttt of ivermectin started within 48 hours of symptoms

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: COVID-19 patients during period of the study more than 18 years old Exclusion Criteria: refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin

Locations (1)

Waheed Shouman

Zagazig, Sharqia Province, Egypt

RECRUITING

Outcomes

Primary Outcomes

time to be symptoms free

duration from day 1 symptoms till 3 days without symptoms

Time frame: within 21 days after enrollment

Secondary Outcomes

hospitalization

need hospital admission

Time frame: within 21 days after enrollement

Mechanical ventilation

need mechanical ventilation

Time frame: within 21 days after enrollement

length of stay

days spent in hospital

Time frame: within one month days after enrollement

mortality

survived or died

Time frame: within one month days after enrollement

Central Contacts

Waheed Shouman, MD

CONTACT

+201114812048 shouman66@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.